Porton Pharma Solutions Ltd. (“Porton”) and Hubei Jianxiang Bioscience Co., Ltd. (“Jianxiang”) jointly announced the launch of the strategic partnership. Focusing on the peptide drug sector, the two parties will join forces to build a one-stop service system covering peptide drug development through to commercial manufacturing, and provide efficient, regulatory-compliant and large-scale customized production solutions for peptide active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical clients worldwide.



The global peptide drug industry is enjoying robust development, with a growing pipeline of innovative drugs and accelerated commercialization progress, driving a sharp surge in market demand for high-standard and large-scale CDMO services.

As a leading global CDMO with deep expertise in complex drug modalities, Porton contributes its established one-stop service platform for peptide and oligonucleotide drug development and production. With state-of-the-art R&D centers and GMP-compliant manufacturing facilities in Shanghai and Chongqing, Porton brings proven end-to-end project delivery excellence, spanning early-stage research and process development through to full regulatory-compliant commercial manufacturing.

Jianxiang, a wholly owned subsidiary of JYMed Technology Co., Ltd., is a specialized manufacturer focused exclusively on commercial-scale peptide API production. The company has deployed substantial strategic investments to build large-scale, high-standard manufacturing infrastructure, featuring 10 commercial-scale production lines and dedicated pilot plants. All facilities are engineered and operated to meet the stringent cGMP standards established by the U.S. FDA, EMA and NMPA, providing the core large-scale production capacity to support global peptide API and intermediate supply.

This strategic partnership will integrate R&D resources, technical strength and manufacturing capabilities in the peptide drug field, and form a close cooperation mechanism through supply chain resource sharing and complementary advantages:

• Unlock Scale Effects: By integrating Porton’s advantages in front-end R&D and client resources with Jianxiang’s strengths in back-end mass production and regulatory compliance, the partnership is expected to build a closed R&D and manufacturing loop, improve delivery efficiency, and strengthen Porton’s core competitiveness in peptide CDMO services.

• Fully Integrated End-to-End CMC Solutions: Leveraging the synergistic capabilities of both parties, the partnership will provide clients with comprehensive CMC (Chemistry, Manufacturing and Controls) solutions covering the entire drug life cycle, shorten industrialization cycles, reduce total project costs, and ensure compliant and stable delivery of peptide drug substances.

This strategic partnership marks a deep synergy and strong alliance between the two parties in the peptide drug sector. It is a key milestone for Porton to deepen its layout in the peptide field and enhance its capabilities in novel molecule development, as well as a new starting point for Jianxiang to embrace ecosystem win-win with an open attitude.

Going forward, the two partners will uphold the philosophy of long-term win-win cooperation, continuously deepen capacity collaboration, technology sharing and project cooperation, and deliver more efficient and reliable one-stop peptide drug CMC solutions to global clients, working together to enable earlier access to good medicines.

About Porton

With over 4,200 employees and 18 operations and commercial offices across the US, EU, and China, Porton Pharma Solutions provides global pharmaceutical and biotech companies with innovative, reliable, and end-to-end process R&D and GMP manufacturing services across Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), as well as Advanced Therapy Medicinal Products.

We are committed to a customer-centric approach and have been recognized through awards by industry forums and global pharmaceutical and biotech companies for our process innovation, supply chain performance, and compliance with global quality and EHS standards. We constantly strive for excellence and enabling earlier access to good medicines.

About Hubei Jiansheng Bioscience Co., Ltd.

Situated in the Xian’an Economic Development Zone, Hubei Jianxiang Bioscience Co., Ltd. is the cornerstone of JYMed Peptide's large-scale peptide API production.Spanning a 300-acre campus with more than 54,000 m² of cutting-edge infrastructure, this site was built from the ground up to support complex peptide synthesis and high-volume production for both commercial and clinical markets.The facility integrates Solid Phase Peptide Synthesis (SPPS) and Liquid Phase Peptide Synthesis (LPPS) technologies, supported by automated preparative chromatography systems, continuous purification processes, and extensive capacity for future expansion.With strict adherence to international CGMP standards, the Hubei site has successfully passed multiple US FDA and NMPA audits, earning its reputation as a reliable partner for pharmaceutical and biotech companies worldwide.